Skip to content

Effects of short-term energy restriction on liver lipids

Effects of short-term energy restriction on liver lipid content, metabolism and inflammatory status in severely obese adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN65605485
Enrollment
100
Registered
2012-05-17
Start date
2012-05-08
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatology, Surgery Surgery

Interventions

Participants will be assigned randomly, to one of two intervention groups to undertake an energy restrictive diet for two weeks pre-operatively: 1. The Derby Hospitals standard pre-bariatric surgical

Sponsors

University of Nottingham (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients accepted for weight loss surgery at Derby Hospitals NHS Foundation Trust 2. Male and female participants 3. Lower age limit = 18 years, no upper age limit

Exclusion criteria

Exclusion criteria: 1. Secondary NAFLD 2. Diabetes mellitus treated by insulin, GLP1 or pioglitazone 3. Excess alcohol intake (exceeding national recommendations) 4. Patients receiving anti-inflammatory medication 5. Pregnancy and lactation 6. Any other condition judged by the investigative team to be clinically significant Exclusions recommended by LighterLife (meal replacement plan): 7.1. Some cardiac conditions (including heart failure, arrhythmias, valve disease, requiring treatment) 7.2. Some cerebrovascular conditions. (Patients who have suffered cerebrovascular disease may participate if the following conditions are met; more than six months has passed and the patient?s condition is stable) 7.3. Schizophrenia, delusional and bipolar disorder, psychosis 7.4. Epilepsy or history of seizure 7.5. Kidney or liver disease (severe) 7.6. Total lactose intolerance 7.7. Type 1 diabetes 7.8. Anorexia or bulimia or other eating disorder undergoing or awaiting treatment. 7.9. Porphyria 7.10. Taking prescribed anticoagulants, digoxin, lithium or monoamine oxidase inhibitors (MAOIs) 7.11. Unstable angina 7.12. Major depressive disorder

Design outcomes

Primary

MeasureTime frame
Fatty Liver Assessment is measured using histological assessment of tissue biopsy and NASH Clinical Research Network scoring system definitions at time of surgery (post-diet).

Secondary

MeasureTime frame
1. Body Weight Change is measured using a Marsden MPMS-300 high capacity weighing scale, before the diet, at the pre-op clinic, and after the diet, on the day of surgery 2. Diet Compliance is measured using a study-specific self-reported questionnaire with visual analogue scale on the day of surgery (post-diet)

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026